Pamela McMahon

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, Boston, MA 02114, USA
    Risk Anal 32:S117-24. 2012
  2. pmc Chapter 13: CISNET lung models: comparison of model assumptions and model structures
    Pamela M McMahon
    Institute of Technology Assessment, 101 Merrimac St, Boston, MA 02114 4724, USA
    Risk Anal 32:S166-78. 2012
  3. ncbi request reprint Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA 02114, USA
    Med Decis Making 26:497-511. 2006
  4. doi request reprint Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 248:278-87. 2008
  5. pmc Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period
    Pamela M McMahon
    Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
    Cancer 113:3440-9. 2008
  6. pmc Cost-effectiveness of computed tomography screening for lung cancer in the United States
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Thorac Oncol 6:1841-8. 2011

Detail Information

Publications6

  1. pmc Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, Boston, MA 02114, USA
    Risk Anal 32:S117-24. 2012
    ..0% (42.0% in men, 33.3% in women). The adoption of annual screening would have prevented less than half as many lung cancer deaths as the elimination of cigarette smoking...
  2. pmc Chapter 13: CISNET lung models: comparison of model assumptions and model structures
    Pamela M McMahon
    Institute of Technology Assessment, 101 Merrimac St, Boston, MA 02114 4724, USA
    Risk Anal 32:S166-78. 2012
    ..This article highlights aspects of the models that are most relevant to similarities of or differences between the results. Structured comparisons can increase the transparency of these complex models...
  3. ncbi request reprint Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA 02114, USA
    Med Decis Making 26:497-511. 2006
    ..This approach is suggested when modeling a disease that causes a large proportion of all-cause mortality, particularly when mortality from the disease of interest and other-cause mortality are both affected by the same risk factor...
  4. doi request reprint Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 248:278-87. 2008
    ....
  5. pmc Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period
    Pamela M McMahon
    Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
    Cancer 113:3440-9. 2008
    ..This study estimated changes in lung cancer outcomes through 2005, had chest CT screening been introduced in 1990...
  6. pmc Cost-effectiveness of computed tomography screening for lung cancer in the United States
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Thorac Oncol 6:1841-8. 2011
    ..Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level...